| 6.065 0.055 (0.92%) | 01-21 10:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.53 |
1-year : | 11.38 |
| Resists | First : | 8.16 |
Second : | 9.75 |
| Pivot price | 7.68 |
|||
| Supports | First : | 5.59 |
Second : | 4.65 |
| MAs | MA(5) : | 6.17 |
MA(20) : | 8.12 |
| MA(100) : | 5.62  |
MA(250) : | 3.56 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 4.5 |
D(3) : | 5.1 |
| RSI | RSI(14): 29.9 |
|||
| 52-week | High : | 9.75 | Low : | 1.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NUVB ] has closed above bottom band by 15.9%. Bollinger Bands are 151.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.09 - 6.12 | 6.12 - 6.16 |
| Low: | 5.52 - 5.56 | 5.56 - 5.6 |
| Close: | 5.94 - 6.01 | 6.01 - 6.07 |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Tue, 20 Jan 2026
Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations - Yahoo Finance
Mon, 19 Jan 2026
Here's What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) - Finviz
Sat, 17 Jan 2026
Is Nuvation Bio (NUVB) Pricing In Its Sharp Swings Or A Long Runway For Growth - Yahoo Finance
Fri, 16 Jan 2026
A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal - Yahoo Finance
Fri, 16 Jan 2026
A Look At Nuvation Bio’s Valuation After The Eisai Taletrectinib Collaboration Agreement - Sahm
Thu, 15 Jan 2026
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 342 (M) |
| Held by Insiders | 2.3159e+008 (%) |
| Held by Institutions | 19 (%) |
| Shares Short | 52,610 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.3155e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -430.2 % |
| Return on Assets (ttm) | -24.9 % |
| Return on Equity (ttm) | -52.5 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 454.64 |
| Sales Per Share | 1.72581e+007 |
| EBITDA (p.s.) | 9.36129e+006 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -190 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 9.8 |
| Dividend | 0 |
| Forward Dividend | 4.174e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|